Literature DB >> 7626000

Evaluation of the use of the luciferase-reporter-gene system for gene-regulation studies involving cyclic AMP-elevating agents.

O Benzakour1, C Kanthou, U Dennehy, A al Haq, L P Berg, V V Kakkar, D N Cooper.   

Abstract

The effects of cyclic AMP (cAMP)-elevating agents on the activity of cis-acting gene promoter sequences are frequently studied using the luciferase-reporter-gene system. The aim of the present study was to assess whether cAMP-elevating agents induce any changes in the level of luciferase activity independently of a transcriptional activation of promoter elements. Chloramphenicol acteyltransferase (CAT) and luciferase reporter genes under the control of the same promoter elements were transiently expressed in primary cultures of human vascular smooth-muscle cells. Transfected cells were treated with a cell-permeable and non-hydrolysable cAMP analogue, 2'-O-monobutyryl-8-bromo cAMP, or with the cAMP-elevating agents forskolin and prostaglandin E1 (PGE1). Forskolin and PGE1 induced a significant increase in the level of luciferase activity, but had no effect on CAT activity. Conclusions based solely on the use of the luciferase-reporter-gene system in studies involving promoter activation by cAMP-elevating agents could therefore be misleading.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7626000      PMCID: PMC1135743          DOI: 10.1042/bj3090385

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

Review 1.  Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins.

Authors:  P J Mitchell; R Tjian
Journal:  Science       Date:  1989-07-28       Impact factor: 47.728

2.  Introns increase gene expression in cultured maize cells.

Authors:  J Callis; M Fromm; V Walbot
Journal:  Genes Dev       Date:  1987-12       Impact factor: 11.361

3.  Advantages of firefly luciferase as a reporter gene: application to the interleukin-2 gene promoter.

Authors:  T M Williams; J E Burlein; S Ogden; L J Kricka; J A Kant
Journal:  Anal Biochem       Date:  1989-01       Impact factor: 3.365

4.  Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA.

Authors:  J P Behr; B Demeneix; J P Loeffler; J Perez-Mutul
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Assay of cyclic AMP by the luciferin-luciferase system.

Authors:  C A Sutherland; R A Johnson
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

Review 6.  Modulation of cellular responses by hormones: role of cAMP specific, rolipram-sensitive phosphodiesterases.

Authors:  C Sette; E Vicini; M Conti
Journal:  Mol Cell Endocrinol       Date:  1994-04       Impact factor: 4.102

7.  Synthesis of active firefly luciferase by in vitro translation of RNA obtained from adult lanterns.

Authors:  K V Wood; J R de Wet; N Dewji; M DeLuca
Journal:  Biochem Biophys Res Commun       Date:  1984-10-30       Impact factor: 3.575

8.  Cloning of firefly luciferase cDNA and the expression of active luciferase in Escherichia coli.

Authors:  J R de Wet; K V Wood; D R Helinski; M DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

10.  Firefly luciferase gene: structure and expression in mammalian cells.

Authors:  J R de Wet; K V Wood; M DeLuca; D R Helinski; S Subramani
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

View more
  1 in total

1.  Analysis of uracil-DNA glycosylases from the murine Ung gene reveals differential expression in tissues and in embryonic development and a subcellular sorting pattern that differs from the human homologues.

Authors:  H Nilsen; K S Steinsbekk; M Otterlei; G Slupphaug; P A Aas; H E Krokan
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.